|Packaging Size||100 Tablets|
|Shelf life||2 Years|
Eudemine (Diazoxide 50 Mg) Tablets are used orally in the treatment of intractable hypoglycaemia.
Diazoxide also causes salt and water retention.
Hypoglycaemia: Eudemine administered orally is indicated for the treatment of intractable hypoglycaemia with severe symptoms from a variety of causes including: idiopathic hypoglycaemia in infancy, leucine-sensitive or unclassified; functional islet cell tumours both malignant and benign if inoperable, extra-pancreatic neoplasms producing hypoglycaemia; glycogen storage disease; hypoglycaemia of unknown origin.
Posology and method of administration
Hypoglycaemia: In hypoglycaemia, the dosage schedule of Eudemine tablets is determined according to the clinical needs and the response of the individual patient. For both adults and children a starting oral dose of 5mg/kg body weight divided into 2 or 3 equal doses per 24 hours will establish the patient's response and thereafter the dose can be increased until the symptoms and blood glucose level respond satisfactorily. Regular determinations of the blood glucose in the initial days of treatment are essential. The usual maintenance dose is 3 - 8mg/kg/day given in two or three divided doses.
Reduced doses may be required in patients with impaired renal function.
In children with leucine-sensitive hypoglycaemia, a dosage range of 15- 20mg/kg/day is suggested.
In adults with benign or malignant islet-cell tumours producing large quantities of insulin, high dosages of up to 1,000mg per day have been used.
In the treatment of hypoglycaemia, Eudemine is contraindicated in all cases which are amenable to surgery or other specific therapy.
Hypersensitivity to any component of the preparation or other thiazides.
Special warnings and precautions for use
In the treatment of hypoglycaemia it is necessary that the blood pressure be monitored regularly.
Retention of sodium and water is likely to necessitate therapy with an oral diuretic such as frusemide or ethacrynic acid. The dosage of either of the diuretics mentioned may be up to 1g daily. It must be appreciated that if diuretics are employed then both the hypotensive and hyperglycaemic activities of diazoxide will be potentiated and it is likely that the dosage of diazoxide will require adjustment downwards. In patients with severe renal failure it is desirable to maintain, with diuretic therapy, urinary volumes in excess of 1 litre daily. Hypokalaemia should be avoided by adequate potassium replacement.
Diazoxide should be used with caution in patients with cardiac failure or impaired cardiac reserve in whom sodium and water retention may worsen or precipitate congestive heart failure. A direct effect on myocardium and cardiac function cannot be excluded.
Diazoxide should be used with care in patients with impaired cardiac or cerebral circulation and in patients with aortic coarctation, aortic stenosis, arteriovenous shunt, heart failure or other cardiovascular disorders in which an increase in cardiac output could be detrimental.
Diazoxide should be administered with caution to patients with hyperuricaemia or a history of gout, and it is advisable to monitor serum uric acid concentration.
Whenever Eudemine is given over a prolonged period regular haematological examinations are indicated to exclude changes in white blood cell and platelet counts.
Also in children there should be regular assessment of growth, bone and psychological maturation.
The very rapid, almost complete protein binding of diazoxide requires cautious dosage to be used in patients whose plasma proteins may be lower than normal.